Form 4: ProKidney Director Sells Over 750K Shares Via Trusts

A director at ProKidney Corp. sold over 750,000 shares of Class A Common Stock through trusts in pre-arranged transactions on November 12 and 13, 2025.

Summary

• Brian J. G. Pereira, a Director of ProKidney Corp. (PROK), reported the sale of 757,162 shares of Class A Common Stock.
• The sales occurred on November 12 and 13, 2025, through two irrevocable trusts: the Brian J. G. Pereira 2012 Irrevocable Trust and the Brian J. G. Pereira 2004 Trust.
• On November 12, 2025, 227,431 shares were sold at a weighted average price of $2.7233 (ranging from $2.70 to $2.88), and 27,595 shares were sold at a weighted average price of $2.7234 (ranging from $2.70 to $2.88).
• On November 13, 2025, 447,803 shares were sold at a weighted average price of $2.37 (ranging from $2.25 to $2.66), and 54,333 shares were sold at a weighted average price of $2.37 (ranging from $2.25 to $2.66).
• Following these transactions, both trusts no longer beneficially own Class A Common Stock.
• The transactions were made pursuant to a Rule 10b5-1(c) pre-arranged trading plan.

Sentiment

Score: 3

Explanation: The sentiment is negative due to significant insider selling by a director, especially with a declining average sale price over the two days of transactions. While executed under a 10b5-1 plan, the sheer volume and price trend can still be perceived as a bearish signal by the market.

Positives

• The transactions were executed under a Rule 10b5-1(c) plan, indicating they were pre-scheduled and not necessarily based on new, non-public information.

Negatives

• A director selling a significant number of shares (757,162 shares) could be perceived negatively by the market, potentially signaling a lack of confidence or a need for liquidity.
• The sale prices on November 13, 2025 ($2.37 weighted average), were lower than those on November 12, 2025 ($2.7233 and $2.7234 weighted average), indicating a declining price trend during the sale period.

Risks

• Significant insider selling can sometimes lead to negative market sentiment and downward pressure on the stock price.

Industry Context

Insider selling is a common occurrence across all industries, often driven by personal financial planning, diversification, or liquidity needs. While a large sale by a director can sometimes raise questions, the use of a 10b5-1 plan suggests a pre-planned, rather than reactive, decision.

Stakeholder Impact

• Shareholders: May interpret the significant insider selling as a negative signal, potentially leading to decreased confidence and downward pressure on the stock price.

Key Dates

Recommendation

The significant volume of shares sold by a director, totaling over 750,000 shares, coupled with a noticeable decline in the average sale price over the two transaction days, suggests a negative outlook from an insider. While executed under a 10b5-1 plan, the sheer scale of the divestment could signal a lack of confidence or a belief that the stock is fully valued or overvalued. This insider action, particularly the declining price trend during the sale, warrants a cautious approach and suggests a 'sell' recommendation for investors, as it could lead to further downward pressure on the stock price.

Keywords

ProKidney Corp, PROK, Insider Selling, Form 4, Director Stock Sale, Brian J. G. Pereira, Equity Transaction, Trust Sale, 10b5-1 Plan